{"id":4100,"date":"2026-11-02T09:00:00","date_gmt":"2026-11-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4100"},"modified":"2026-11-05T20:35:30","modified_gmt":"2026-11-06T00:35:30","slug":"dual-gated-crispr-delivery-raises-tumor-mhc-i-in-mice","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4100","title":{"rendered":"Dual Gated CRISPR Delivery Raises Tumor MHC I in Mice"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Yin Lab (academic, China)<\/p>\n

Event Type<\/strong><\/p>\n

Peer-reviewed publication (JACS)<\/p>\n

Modality<\/strong><\/p>\n

CRISPR-Cas9 mRNA lipid nanoparticle delivery<\/p>\n

Asset<\/strong><\/p>\n

APE1-gated SDHC editing system<\/p>\n

Target<\/strong><\/p>\n

SDHC; MHC-I antigen presentation<\/p>\n

Disease Area<\/strong><\/p>\n

Melanoma (B16-OVA mouse model)<\/p>\n

Summary<\/h4>\n

Previously missed November 2 online JACS paper from a China-based academic team: a two-stage targeting system activated CRISPR guide RNA in APE1-rich tumor cells and used bioorthogonal lipid-particle anchoring to deliver Cas9 mRNA. In a B16-OVA mouse melanoma model, SDHC disruption increased MHC-I antigen-presentation signals and T-cell-mediated antitumor activity. Human feasibility is untested.<\/p>\n

The study shielded an SDHC guide RNA with APE1-responsive complementary DNA and packaged it with Cas9 mRNA in dibenzocyclooctyne-decorated lipid nanoparticles. A separate azido-sugar pretreatment labeled tumor cells to promote click-mediated particle binding. The published abstract reports selective SDHC editing, altered succinate-linked epigenetic and transcriptional programs, and increased MHC-I presentation in the mouse model. The paper was published online November 2; no later syndication is treated as the original date.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation A:<\/strong> combining biochemical guide activation and cell-surface delivery targeting could reduce normal-tissue editing while restoring antigen visibility to cytotoxic T cells. The mechanistic steps and in-vivo B16-OVA effect support experimental feasibility. Counterargument: the immunogenic ovalbumin model and engineered azido labeling may overstate translation to heterogeneous human tumors.<\/p>\n

Interpretation B:<\/strong> the work chiefly validates a modular targeting architecture, not SDHC as a treatment target. Two sequential delivery agents, APE1 heterogeneity and potential metabolic harm from permanent SDHC knockout support caution. Human tumor versus normal editing maps, off-target sequencing, durable metabolic toxicity, repeated-dose immunogenicity, PK\/PD, biodistribution and scalable manufacturing would test the thesis.<\/p>\n

Company and Product Background<\/h4>\n

The academic work concerns melanoma immune escape. SDHC encodes a subunit of mitochondrial succinate dehydrogenase; disrupting it changes succinate metabolism and is proposed to increase MHC-I antigen presentation. MHC-I presents intracellular peptides to CD8 T cells.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Peer-reviewed academic preclinical evidence, not a trial or regulatory filing.<\/li>\n
  • The disclosed in-vivo efficacy is in an engineered mouse melanoma model.<\/li>\n
  • Permanent editing of a mitochondrial metabolic gene introduces a distinct safety question.<\/li>\n
  • No human exposure, therapeutic window, licensing status or manufacturing process was disclosed.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    A material delivery-and-activation concept for tumor-restricted editing. Its two-step logistics and safety of SDHC loss are the main barriers to a credible treatment path.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: positive for preclinical proof of concept; uncertain for treatment potential. Confidence in Facts: high for the peer-reviewed published abstract. Confidence in Interpretation: low because clinical portability and off-target risk are unknown.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Previously missed November 2 online JACS paper from a China-based academic team: a two-stage targeting system activated CRISPR guide RNA in APE1-rich tumor cells and used bioorthogonal lipid-particle anchoring to deliver Cas9 mRNA. In…<\/p>\n","protected":false},"author":1,"featured_media":4101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[366,1392,1391],"class_list":["post-4100","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-crispr","tag-sdhc","tag-yin-lab"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4100"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4100\/revisions"}],"predecessor-version":[{"id":4122,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4100\/revisions\/4122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4101"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}